Nitride-Based Raman Biochip for Lung Cancer Diagnosis and Monitoring

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorTaichung Veterans General Hospital

About this trial

This prospective, multicenter observational study aims to evaluate the diagnostic and clinical monitoring performance of a nitride-based Raman biochip in participants with and without lung cancer. Peripheral blood samples will be collected and analyzed using the Raman biochip to characterize molecular spectral patterns and assess their association with the current standard diagnosis of lung cancer.

The study plans to enroll 2,000 participants with pathologically confirmed lung cancer and 1,000 participants without lung cancer. Diagnostic performance will be evaluated using measures including sensitivity, specificity, positive predictive value, negative predictive value, and receiver operating characteristic curve analysis. Exploratory analyses will assess performance according to lung cancer histological subtype, disease stage, and longitudinal clinical status.

Eligibility criteria

Qualifiers

Age 18 years or older.

Underwent low-dose computed tomography or chest computed tomography within the previous 2 years.

Pathologically confirmed lung cancer.

Histological diagnosis of adenocarcinoma, squamous cell carcinoma, or small cell lung cancer, with TNM stage determined by a thoracic physician.

Disqualifiers

1. Younger than 18 years of age. 2. Unable to understand the study information or provide written informed consent.

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

3,000 Participants
are grouped into 2 trial groups

Sponsors and collaborators

Taichung Veterans General Hospital

Lead sponsor

Far Eastern Memorial Hospital

Collaborator

Taoyuan General Hospital, Ministry of Health and Welfare

Collaborator